Daratumumab
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Daratumumab
Daratumumab: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Daratumumab, so there is currently no new predicted indication. The drug’s own recorded uses are listed below. They come from licence records and are not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 2 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| multiple myeloma | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| plasma cell myeloma |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 12220E | Darzalex | Solution concentrate for I.V. infusion 1 | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy / immunotherapy (anti-CD38 monoclonal antibody), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Please refer to the PI; full blood count monitoring is generally expected in myeloma care |
| Handling Protection | Please refer to the PI and local institutional policy |
Safety Considerations
- Drug Interactions: 81 interactions were identified. Examples rated Major include deferiprone, samarium (153Sm) lexidronam, adalimumab, baricitinib, certolizumab pegol and cladribine. Examples rated Moderate include strontium chloride Sr-89, roflumilast, chloramphenicol, zidovudine, azathioprine, alemtuzumab, ganciclovir and several vaccines (such as anthrax and live cholera vaccines). Only 20 of the 81 interactions were available for review.
For warnings and contraindications, please refer to the TGA-approved Product Information (PI).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.